INC Research Files Registration Statement for Initial Public Offering
INC Research Holdings, Inc. (INC Research), a leading, global Phase I to IV contract research organization, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) related to a proposed initial public offering of its common stock. The number of shares to be offered by INC Research
INC Research Holdings, Inc. (INC Research), a leading, global Phase I to IV contract research organization, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) related to a proposed initial public offering of its common stock. The number of shares to be offered by INC Research and its stockholders and the price range for the offering have not yet been determined. The Company has applied to list its common stock on The NASDAQ Global Market under the ticker symbol “INCR.” INC Research expects to use the net proceeds it receives from the offering to refinance its existing long-term debt as further specified in the registration statement.
Goldman, Sachs & Co. and Credit Suisse are serving as joint lead book-running managers for the offering. Baird, William Blair and Wells Fargo are serving as co-managers for the offering.
The offering will be made only by means of a prospectus. Once available, copies of the preliminary prospectus relating to the offering may be obtained from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, phone: 866-471-2526, email: [email protected]; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, phone: 800-221-1037, email: [email protected]
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
